The role of imatinib in the treatment of pulmonary hypertension

Drugs of Today

Volumn 49, Issue 3, 2013, Pages 203-211

  Mucke, H ^a  

^a H M Pharma Consultancy   (Austria)

Author keywords

Blood oxygenation; Imatinib mesylate; Peripheral artery smooth muscle cells; Pressure overload; Pulmonary arterial hypertension

Indexed keywords

BOSENTAN; DIURETIC AGENT; GLYCOGEN SYNTHASE KINASE 3; ILOPROST; IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SILDENAFIL;

CARDIOPULMONARY HEMODYNAMICS; CHRONIC MYELOID LEUKEMIA; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; ENZYME PHOSPHORYLATION; EXERCISE; GLYCOGEN STORAGE DISEASE TYPE 1; HEART ARREST; HEART ATRIUM FLUTTER; HEART FAILURE; HEART INDEX; HEART OUTPUT; HEART VENTRICLE FAILURE; HEART WEIGHT; HUMAN; IN VITRO STUDY; LUNG HEMODYNAMICS; PERIPHERAL EDEMA; PROTEIN EXPRESSION; PRURITUS; PULMONARY HYPERTENSION; REVIEW; THERAPY EFFECT; UPREGULATION;

BLOOD OXYGENATION; IMATINIB MESYLATE; PERIPHERAL ARTERY SMOOTH MUSCLE CELLS; PRESSURE OVERLOAD; PULMONARY ARTERIAL HYPERTENSION;

ANIMALS; BENZAMIDES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; HYPERTENSION, PULMONARY; MUSCLE, SMOOTH, VASCULAR; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 84875690569     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.3.1937430     Document Type: Review

References (27)

1. Badesch, D.B., Raskob, G.E., Elliott, C.G. et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010, 137(2): 376-87.
2. Schermuly, R.T., Ghofrani, H.A., Wilkins, M.R., Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011, 8(8): 443-55.
3. Yu, Y., Sweeney, M., Zhang, S., Platoshyn, O., Landsberg, J., Rothman, A., Yuan, J.X. PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am J Physiol Cell Physiol 2003, 284(2): C316-30.
4. Rai, P.R., Cool, C.D., King, J.A. et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2008, 178(6): 558-64.
5. Piccaluga, P.P., Rondoni, M., Paolini, S., Rosti, G., Martinelli, G., Baccarani, M. Imatinib mesylate in the treatment of hematologic malignancies. Expert Opin Biol Ther 2007, 7(10): 1597-611.
6. Schermuly, R.D., Dony, E., Ghofrani H.A. et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115(10): 2811-21.
7. Skelkiewicz, P., Shermuly, R.T., Tian, X. et al. Glycogen synthase kinase 3beta contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension. PLoS One 2011, 6(4): e18883.
8. Dahal, P.K., Heuchel, R., Pullamsetti, S.S. et al. Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-b. Pulm Circ 2011, 1(2): 259-68.
9. Gambaryan, N., Perros, E., Montani, D., Cohen-Kaminsky, S., Mazmanian, G.M., Humbert, M. Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension. Eur Respir J 2010, 36(5): 1209-11.
10. Ciuclan, L., Hussey, M.J., Burton, V. et al. Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression. Am J Respir Crit Care Med 2013, 187(1): 78-89.
11. Kwapiszewska, G., Markart, P., Dahal, B.K. et al. PAR-2 inhibition reverses experimental pulmonary hypertension. Circ Res 2012, 110(9): 1179-91.
12. Abe, K., Toba, M., Alzoubi, A. et al. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am Respir Cell Mol Biol 2011, 45(4): 804-8.
13. Nakamura, K., Akagi, S., Ogawa, A. et al. Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2012, 159(2): 100-6.
14. Ghofrani, H.A., Seeger, W., Grimminger, F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005, 353(13): 1412-3.
15. Souza, R., Sitbon, O., Parent, F. et al. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006, 61(8): 736.
16. Krauth, M.T., Binder, T., Ohler, L., Jäger, U., Valent, P: Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy. Leuk Res 2008, 32(11): 1779-83.
17. García Hernández, F.J., Castillo Palma, M.J., González León, R., Garrido Rasco, R., Ocaña Medina, C., Sánchez Román, J. Experience with imatinib to treat pulmonary arterial hypertension. Arch Bronconeumol 2008, 44(12): 689-91.
18. ten Freyhaus, H., Dumitrescu, D., Bovenschulte, H., Erdmann, E., Rosenkranz, S. Significant improvement of right ventricular function by imatinib mesylate in scleroderma- associated pulmonary arterial hypertension. Clin Res Cardiol 2009, 98(4): 265-7.
19. Hatano, M., Yao, A., Shiga, T., Kinugawa, K., Hirata, Y., Nagai, R. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J 2010, 51(4): 272-6.
20. Ghofrani, H.A., Morrell, N.W., Hoeper, M.M. et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010, 182(9): 1171-7.
21. Hoeper, M., Barst, R., Bourge, R. et al. Imatinib improves exercise capacity and hemodynamics at 24 weeks as add-on therapy in symptomatic pulmonary arterial hypertension patients: the IMPRES study. Chest 2011 (Oct 22-26, Honolulu) Abst 1045A.
22. Hoeper, M., Barst, R., Galiè, N. et al. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. Annu Congr Eur Respir Soc (Sept 1-5, Vienna) 2012, Abst 3270.
23. Shah, A.M., Campbell, P., Peacock, A. et al. Effect of imatinib as add-on therapy on echocardiographic measures of RV function in patients with advanced PAH: The IMatinib in Pulmonary arterial hypertension, a Randomized Efficacy Study (IMPRES) echocardiography sub-study. Heart Failure Congress 2012 (May 19-22, Belgrade) 2012.
24. Kerkelä, R., Grazette, L., Yacobi, R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12(8): 908-16.
25. Estabragh, Z.R., Knight, K., Watmough, S.J., Lane, S., Vinjamuri, S., Hart, G., Clark, R.E. A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. Leuk Res 2011, 35(1): 49-51.
26. Hu, W., Lu, S., McAlpine, I. et al. Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c- Abl kinase. Toxicol Sci 2012, 129(1): 188-99.
27. Fortenko, O.M., Melendres-Groves, L., Richter, A., Liao, X., Spiekerkoetter, E., Zamanian, R., De Jesus Perez, V.A. Development of a recurrent pleural effusion in a patient with pulmonary arterial hypertension treated with imatinib. Case Rep Clin Med 2012, 1(2): 38-41.